Skip to content

UVA Brain and Aortic Aneurysm Study

The University of Virginia Brain and Aortic Aneurysm Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02869464
Acronym
BAAS
Enrollment
360
Registered
2016-08-17
Start date
2014-04-30
Completion date
Unknown
Last updated
2016-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Aortic Aneurysm, Intracranial Aneurysm

Keywords

Aneurysm, Intracranial Aneurysm, Abdominal Aortic Aneurysm

Brief summary

The purpose of this study is to examine the percentage of patients who present with abdominal aortic aneurysms (AAA) will also have intracranial aneurysms (IA) and conversely; to examine the percentage of patients who present with intracranial aneurysms will also have abdominal aortic aneurysms.

Detailed description

The investigators have previously generated estimates for cost effectiveness of each arm of this reciprocal screening protocol based on literature dervied estimates of coprevalence and other key factors in a decision tree model to compare costs and outcomes. They measured expected outcomes using quality-adjusted life years (QALY) and the incremental cost-effectiveness ratios (ICER). The current study will involve establishment of the true co-prevalence and recalculation of the ICERs and QALYs. Based on their literature derived models we previously found an ICER of $34.01/QALY for AAA screening in IA patients and an ICER of $6,401.91/QALY for IA screening in AAA patients. Both of these are well below the societal accepted threshold of $60,000/QALY. However, both models were sensitive to co-prevalence. In the current study the investigators will therefore determine the actual cost-effectiveness of performing additional radiographic procedures and genetic counseling. The investigators will also bank DNA and RNA for future research.

Interventions

OTHERImaging-Ultrasound

Abdominal Ultrasound

OTHERImaging-MRA

Non-contrast Enhanced Magnetic Resonance Angiogram

GENETICDNA, RNA testing

To test for the co-prevalence of shared genetic markers in afflicted populations.

Sponsors

University of Virginia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Clinical and radiographic diagnosis of either abdominal aortic aneurysm (AAA) or intracranial cerebral aneurysm (IA). Aneurysm may be symptomatic (s/p rupture or mass effect) or asymptomatic (detected as part of screening or incidentally discovered. Aneurysms int he brain may be multiple. AAA will be defined as \>= 3 cm by any imaging modality. IA will be defined as \>= 3 mm on any imaging modality. * Able to provide a valid informed consent (self or legally authorized representative)

Exclusion criteria

* Contra-indication for MRI/A (embedded metal, intractable claustrophobia, pacemaker, etc.) * Intracranial aneurysm associated with arteriovenous malformation * Clinical or radiographic diagnosis of mycotic aneurysm * Substantial pre-existing neurological or psychiatric illness that would confound neurological assessment or other outcome assessment. * Other serious conditions that make the patient unlikely to survive long enough to benefit from the screening program. * Inability to follow the protocol or return for screening test or genetic counseling. * Unwilling to have reports from imaging and genetic counselor sent to a clinician (PCP, testing surgeon, etc) Note: Pregnancy is not a reason to exclude, but imaging done for the study will be postponed until after the subject has given birth.

Design outcomes

Primary

MeasureTime frameDescription
Revised cost-effective analysis measured in dollars/quality adjusted life years (QALY)2 yearsRevision of cost effective analysis for screening for AAA in those presenting with IA and for screening for IA in those with AAA.

Secondary

MeasureTime frameDescription
Analysis of Covariates for co-prevalence of aneurysms measured as present or absentYear 2Analysis of covariates associated with co-prevalence of aneurysms in both territories.
Biorepository (samples stored in freezer)Year 2Develop a biorepository of DNA and RNA for individuals presenting with either IA or AAA, allowing specific future testing of shared genetic risk factors.

Countries

United States

Contacts

Primary ContactClaire L McKinley, C.C.R.P.
cw9ne@hscmail.mcc.virginia.edu434-924-9271
Backup ContactJulia Krupa, M.S.
jkk8d@virginia.edu434-924-4023

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026